drugset / Trial / NCT05557370

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370

Phase 4 Active not recruiting 30 enrolled Medical College of Wisconsin Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelPrevention

Summary

To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.

Timeline

Start
2023-06-01
Primary completion
2028-12-31
Completion
2035-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil 9 Vaccine